title: Interview: an insight into cutting-edge tuberculosis vaccine research. Interview by Katie Lockwood.
abstract: Else Marie Agger speaks to Katie Lockwood, Assistant Commissioning Editor Else Marie Agger was appointed Director of the Department of Infectious Disease Immunology, Statens Serum Institut in Denmark in 2011. Prior to this, she had been heading two different research groups focusing on tuberculosis (TB) vaccine research and adjuvant development, respectively. She holds a postdoctoral degree within immunology from the University of Copenhagen (Denmark). Agger has extensive experience within adjuvant research, TB vaccine research and preclinical development of vaccines. In addition, she has previously been involved in antigen discovery, primarily with a focus on developing novel diagnostic tests within TB. She has been involved in the coordination of vaccine delivery optimization within the EU-funded TBVAC and NEWTBVAC consortia and also has previous experience as a work-package leader within an EU-funded project, focusing on adjuvantation of influenza vaccines. Agger is the coinventor of several adjuvant patents and has published more than 60 papers within TB, vaccines and adjuvant research.
authors.forename: Else Marie
authors.initials: EM
authors.lastname: Agger
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000627:therapeutic use; D000818:Animals; D003718:Denmark; D016503:Drug Delivery Systems; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006017:Glycolipids / Q000627:therapeutic use; D006801:Humans; D007156:Immunologic Memory; D008863:Microspheres; D012106:Research; D058504:Th17 Cells / Q000276:immunology*; D032581:Tuberculosis Vaccines
chemical_list: D000277:Adjuvants, Pharmaceutic; D018984:Epitopes, T-Lymphocyte; D006017:Glycolipids; D032581:Tuberculosis Vaccines; C507803:trehalose 6,6'-dibehenate